Clinical trials: Kidney Failure,Chronic
Uremic Pruritus
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session.
- Trial name
- KALM-2 (NCT03636269)
- Testing
- CR845 0.5 mcg/kg
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 473 people
- Sponsor
- Cara Therapeutics, Inc.
Renal Insufficiency, Chronic
Catheter System Feasibility Clinical Trial
Feasibility clinical study to evaluate the safety and effectiveness of the catheter system for the percutaneous creation of an arteriovenous fistula for patients with end stage renal disease requiring dialysis access.
- Trial name
- NCT02816398
- Testing
- Percutaneous creation of an arteriovenous fistula
- Volunteers
- 26 people
- Sponsor
- Medtronic Endovascular
Chronic Kidney Disease, End-Stage Renal Disease
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania. The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health…
- Trial name
- OPPORTUNITY (NCT00503698)
- Testing
- somatropin
- Where
- 381 sites in United States, Argentina and 19 more
- Volunteers
- 712 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Diseases
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage…
- Trial name
- Clarion-CKD (NCT04968184)
- Testing
- KBP-5074
- Where
- 215 sites in United States, Australia and 20 more
- Volunteers
- 666 people
- Sponsor
- Novo Nordisk A/S
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Post-Approval Study for the FLAIR Endovascular Stent Graft
The purpose of this study is to confirm the long-term safety and effectiveness of the FLAIR Endovascular Stent Graft for treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous (AV) access grafts.
- Trial name
- RENOVA (NCT00677235)
- Testing
- FLAIR Endovascular Stent Graft, PTA
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- C. R. Bard
End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are…
- Conditions
- End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease, Dialysis; Complications
- Trial name
- NCT05225298
- Testing
- Offering SARS-CoV-2 test
- Where
- United States
- Volunteers
- 2,389 people
- Sponsor
- Stanford University
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Acute Kidney Disease, Chronic Kidney Disease
Shear Wave Elastography in Native Kidney Disease
In this proposal, the aim is to examine shear wave elastography (SWE) measurements in diseased native kidneys and correlate them with grades of fibrosis using histological samples.
- Trial name
- NCT02830438
- Testing
- Shear wave elastography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Albert Einstein Healthcare Network
Type 2 Diabetes, Chronic Kidney Disease
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
- Trial name
- AWARD-7 (NCT01621178)
- Testing
- Dulaglutide, Insulin glargine, Insulin lispro
- Where
- 89 sites in United States, Brazil and 7 more
- Volunteers
- 577 people
- Sponsor
- Eli Lilly and Company
Kidney Insufficiency, Secondary Hyperparathyroidism
Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice
The purpose of this study is to obtain data on the safety and effectiveness of Zemplar® (paricalcitol) injection and paricalcitol capsules in real-life clinical practice.
- Trial name
- TOP (NCT01083849)
- Where
- 87 sites in Austria, Germany
- Volunteers
- 761 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease
Measurement of Kidney Blood Flow and Oxygen Levels by MRI
Comparison of renal blood flow measurements by PAH clearance and MRI
- Trial name
- NCT01318967
- Testing
- Furosemide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University
Chronic Kidney Disease, Metabolic Acidosis
Bicarbonate Administration in CKD
Low serum bicarbonate levels, even within the normal laboratory range, are strongly associated with increased risks of hypertension, endothelial dysfunction, cardiovascular disease and death.
- Trial name
- NCT02915601
- Testing
- Sodium bicarbonate
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD3 (NCT03242252)
- Testing
- Sotagliflozin
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 787 people
- Sponsor
- Lexicon Pharmaceuticals
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
- Trial name
- NCT02648347
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 439 sites in United States, Argentina and 18 more
- Volunteers
- 1,751 people
- Sponsor
- Akebia Therapeutics
Hypertension, Chronic Kidney Disease
Genetic Testing to Understand and Address Renal Disease Disparities
In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of…
- Conditions
- Hypertension, Chronic Kidney Disease, Genomics
- Trial name
- GUARDD (NCT02234063)
- Testing
- Immediate Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 2,052 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cardiovascular Disease, Chronic Kidney Disease
Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
The goal of this proposal is to investigate the potential for ACE-inhibitors (ACE-I)(drugs primarily used to treat hypertension or congestive heart failure) to prevent or delay cardiovascular disease (CVD) in older adults with…
- Trial name
- NCT00874432
- Testing
- angiotensin converting enzyme inhibitor, lisinopril
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Secondary Hyperparathyroidism, Chronic Kidney Disease
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who…
- Trial name
- EVOLVE (NCT00345839)
- Testing
- Cinacalcet
- Volunteers
- 3,883 people
- Sponsor
- Amgen
Chronic Kidney Disease
Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function
The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.
- Trial name
- NCT00586261
- Testing
- Pioglitazone, Nitroglycerin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Renal Failure
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.
- Trial name
- NCT00240331
- Testing
- 10mg Rosuvastatin
- Where
- 239 sites in Australia, Austria and 23 more
- Volunteers
- 2,776 people
- Sponsor
- AstraZeneca
Anemia of Chronic Kidney Disease
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects…
- Trial name
- NCT02268994
- Testing
- ferric citrate
- Where
- 36 sites in United States
- Volunteers
- 234 people
- Sponsor
- Keryx Biopharmaceuticals